Clinical Trial

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

Study acronym: HLD-0117
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.
Protocol Amendment History 1 change
notable Sponsor changed: Halda Therapeutics OpCo, Inc. -> Janssen Research & Development, LLC 2026-07-26
Trial Details
NCT Number NCT07524855
Lead Sponsor Halda Therapeutics OpCo, Inc.
Conditions Metastatic Breast Cancer
Enrollment 33 participants
Start Date 2026-04-09
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-02